CHO-S [suspension]

A clonal isolate, derived from Chinese hamster ovary (CHO K1) cells. The CHO-S parental cell line was selected for growth and transfection efficiency. CHO-S cells are adapted to serum-free suspension culture.

Cell Type:
Ovary Epith.
Tissue Origin:
Research Area:
Cancer Research/Cell Biology
Cell Characteristics:

Recommended Media

Developed for low density (clonal) growth of CHO cells.

Storage = 2ºC to 8ºC

12-618 = with L-glutamine
BE02-014 = with UltraGlutamine I, without thymidine

Ham's F12 Medium is a nutrient mixture designed to cultivate a wide variety of mammalian and hybridoma cells (including low density (clonal) growth of CHO cells) when used with serum in combination with hormones and transferrin.

ProCHO™ Protein-free CHO Media were developed specifically to facilitate the production and downstream processing of recombinant proteins expressed in CHO cells. These protein-free formulations support high-density cultures without the need for animal derived components.
Very low levels of recombinant insulin facilitate both downstream purification and regulatory compliance.

The following media systems are available:
- ProCHO™ 4 Medium – For concurrent transition of adherent CHO cells to serum-free and suspension culture; supports faster doubling times
- ProCHO™ 5 Medium – For CHO cells already growing in suspension; supports increased protein production
- ProCHO™ AT Medium – For adherent culture of CHO cells

Storage = 2°C to 8°C

12-029Q - ProCHO™ 4 with phenol red and 0.1% Pluronic® F-68; but without L-glutamine, hypoxanthine, or thymidine.
04-919Q - ProCHO™ 4 with 0.1% Pluronic® F-68; and without phenol red, L-glutamine, hypoxanthine, or thymidine.

12-766Q - ProCHO™ 5  with 0.1% Pluronic® F-68; and without L-glutamine, phenol red, hypoxanthine, or thymidine.
BE15-766 - ProCHO™ 5 powder without phenol red

BE02-016 - ProCHO™-AT contains L-glutamine and does not contain hypoxanthine or thymidine.

PowerCHO™ Chemically Defined, Serum-free and hydrolysate-free CHO Media are non-animal origin media designed to support the growth of CHO cell lines, particularly high-density suspension cultures.

For therapeutic bioprocessing applications, these protein-free formulations also facilitate both downstream purification and regulatory compliance.

Storage = 2°C to 8°C

12-770Q - PowerCHO™-1 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
12-771Q - PowerCHO™-2 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
BE15-771N - PowerCHO™-2 powder (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
12-772Q - PowerCHO™-3 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)

BE12-776Q - PowerCHO™-GS (with HEPES and Pluronic® F-68, without insulin, phenol red or L-glutamine)
PowerCHO™ -GS is designed for use with Lonza's Proprietary GS Gene Expression System™.

12-929Q - PowerCHO™ - Advance

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SG 96-FF-137 2e6 80-92% 43-77% Plasmid (general) 20 µl Shuttle


2e6 80-92% 43-67% Plasmid (general) 20 µl 4D X-Unit
V U-024 1e6 90-98% 67-72% Plasmid (general) 5 µg 100 µl I/II/2b


Serum-free and Speciality Media 
Terme M1, Dorvillius M2, Cochonneau D3, Chaumette T4, Xiao W5, Diccianni MB6, Barbet J3, Yu AL7, Paris F3, Sorkin LS8, Birklé S4. 
PLoS ONE (2014) 9 (2): e103395 
Serum-free and Speciality Media 
Pasche N1, Wulhfard S, Pretto F, Carugati E, Neri D. 
Clin Cancer Res (2012) 18(15): 4092-103 
Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, Rebar EJ, Gregory PD, Klug A, Collingwood TN 
Proc Natl Acad Sci USA (2008) 105(15): 5809-14 
Lattenmayer C, Loeschel M, Schriebl K, Sterovsky T, Trummer E, Vorauer-Uhl K, Muller D, Katinger H, Kunert R 
Biotechnol Bioeng (2007) 96(6): 1118-1126 
Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, Cortesini R, Suciu-Foca N 
J Immunol (2006) 176(5): 2790-8 
Rosenblum MD, Woodliff JE, Madsen NA, McOlash LJ, Keller MR and Truitt RL 
J Invest Dermatol (2005) 125(6): 1130-1138